"Somos una institución prestadora de servicios de salud de alta complejidad, con los más altos estándares de calidad, comprometidos con brindar atención humana y segura para nuestros usuarios."

During the past decade, FOSCAL conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 2 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 1 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "FOSCAL" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Fundación Cardioinfantil Instituto de Cardiología" with 2 trials sponsored, "Edesa Biotech Inc." with 1 trials sponsored, "Fresenius Kabi" with 1 trials sponsored and "Geron Corporation" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "FOSCAL" #1 collaborator was "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator, "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator, "Global Alliance for Chronic Diseases (GACD)" with 1 trials as a collaborator, "Grand Challenges Canada" with 1 trials as a collaborator and "JSS Medical Research Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "FOSCAL" are "COVID-19" (2 trials), "ARDS" (1 trials), "Caloric Deficit" (1 trials), "Cardiovascular Disease" (1 trials) and "Diffuse Large B-Cell Lymphoma" (1 trials). Many other conditions were trialed in "FOSCAL" in a lesser frequency.

Most popular intervention types in "FOSCAL" are "Drug" (5 trials), "Other" (4 trials), "Behavioral" (1 trials), "Biological" (1 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Obinutuzumab" (2 trials), "Placebo" (2 trials), "Prednisone" (2 trials), "Acetaminophen" (1 trials) and "Best Available Therapy (BAT)" (1 trials). Other intervention names were less common.

The vast majority of trials in "FOSCAL" are 10 trials for "All" genders.

Currently, there are NaN active trials in "FOSCAL". undefined are not yet recruiting, 3 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in FOSCAL, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in FOSCAL, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".